📰 Main Study News

Main Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Main Study. Real-time updates on events, politics, business and more.

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

November 27, 2023

—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests of liver injury/inflammation and...

United States San Francisco Hank Mansbach Annie Chang Sheryl Seapy Drug Administration

Source: marketscreener.com

89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details - 89bio (NASDAQ:ETNB)

November 27, 2023

89bio Inc&nbsp;(NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with&nbsp;

Main Study Extension Phase

Source: benzinga.com